undamentalytics Newsletter
Sign in

Proqr Therapeutics N.V. revenue

Proqr Therapeutics N.V.'s revenue was $18.0m in fiscal 2025, down 12.1% on the year before. Since fiscal 2021 ($1.6m) it has grown at a compound 83.7% a year.

Revenue history

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025
Revenue2472018
Growth on the year before—+139.7%+86.1%+190.3%−12.1%

Revenue as reported in the company's 10-K and 10-Q filings (for banks, net interest income plus non-interest income). Growth is left blank when the earlier figure was zero or negative.

Revenue against peers

Biotechnology: the closest covered companies by revenue. Last twelve months.

CompanyRevenueGrowth3-year growth a year
Proqr Therapeutics N.V. $18.0m -12.1% —
Cytomx Therapeutics, Inc. $18.3m -87.0% -38.7%
Celularity Inc $18.7m -58.1% 7.2%
Scynexis Inc $19.2m 489.8% -47.9%
Keros Therapeutics, Inc. $14.9m -93.6% —
Alector, Inc. $13.9m -82.9% -48.6%

Compare with peers

Head to head: CTMX vs PRQRCELU vs PRQRPRQR vs SCYXKROS vs PRQR

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Proqr Therapeutics N.V.'s SEC filings (10-K and 10-Q), retrieved November 1, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Proqr Therapeutics N.V.